Background and Aim: The present study investigated the influence of liver tumor structure on life expectancy in dogs. Diseases of the liver comprise 5-25% of all non-communicable diseases in dogs, and primary hepatic tumors account for 0.6-1.3% of tumors. This research aimed to study the post-operative life span of animals with primary or metastatic tumors of the liver. Materials and Methods: During the study period, 7124 oncological operations were performed in our clinic. In total, 128 liver tumors were detected in live animals, while 323 were detected posthumously. Forty animals underwent surgery for various liver tumors. In dogs with primary liver tumors, the average age was 11.9 years and the average body weight was 15.5 kg, while in dogs with liver metastases, the mean age was 11.4 years and the average body weight was 24 kg. Results: The ratio of males to females among dogs with primary liver tumors was about 1:1 (ten females and nine males), while that among dogs with metastatic liver damage was clearly predominantly female (14 females and two males) because females often undergo surgery for cancerous mammary glands or ovaries. Conclusion: The size of tumors and the number of affected lobes had a significant effect on the post-operative life span. With a tumor size of <5 cm and a lesion covering less than two lobes of the liver, life expectancy was significantly longer and the prognosis was more favorable. In cases of large tumors or those affecting more than two lobes, life expectancy was significantly reduced and the prognosis was cautious to unfavorable.

No abstract

No abstract

Transfusion of allogenic bone marrow to prevent metastasizing of osteogenic sarcoma was studied as an alternative to aggressive chemotherapy in cases when it is impossible to preserve the limb. The study was carried out on 62 dogs with spontaneous osteogenic sarcoma. A single preoperative transfusion of allogenic bone marrow was carried out in 42 dogs one day before the limb amputation and 20 animals were treated by surgery alone (amputation or exarticulation). All the animals were observed for the rest of their lives. In comparison with the control, in the group treated by bone marrow transfusion the median of metastases-free period was notably longer: 20 dogs survived for a long time, some of them died from natural causes in old age. Relative indications for bone marrow transfusion in osteogenic sarcoma are defined with consideration for age and tumor volume. Key Words: osteogenic sarcoma; bone marrow transfusion; metastasesDespite the progress in the treatment of osteogenic sarcoma (OS), this therapy requires further improvement [4,7,8]. The potential of the bone marrow (BM) transfusion, an alternative of intensive chemotherapy, has been studied [1].Hematogenic metastases to the lungs of highly malignant sarcoma in Syrian hamsters were suppressed by a single transfusion of intact BM cells from normal allogenic donors. The BM cells effectively suppress metastases to the lungs represented by individual or small groups of cells, but the treatment is ineffective after formation of micrometastases [1]. A three-year survival improved in 24 patients treated by transfusions of allogenic BM in comparison with patients treated by surgery [2]. Further course of disease after treatment with BM Oncology Research Center, Russian Academy of Medical Sciences, Moscow was not reported. We studied the remote results of the treatment with BM transfnsions. Dogs with spontaneous OS, a classical analog of human tumors with helnatogenic metastases, but with a 4-6 times more rapid progress [6] were observed.Our purpose was to evaluate the remote results, the outcome of treatment, and the prospects for the application of this method. We evaluated the effectiveness of preoperative transfusion of whole (BMw) and separated (BMs) BM, the relationship between the treatment effectiveness and animal age and the tumor size, and defined the hldications for BM transfusions h~ the treatment of osteosarcoma in hunmns. MATERIALS AND METHODSThe study was carried out in 62 dogs with spontaneous OS. The animals were treated at the Experimental Therapy Clinic of the Oncology Research